Clinical Research Directory

Inclusion Criteria: * Adult patients (\>18 years old). * Non-respectable Stage III and IV NSCLC. * Patients ECOG PS of 0-2. * With no-actionable or unknown driver mutation * Planned to receive platinum doublets with or without immune checkpoint inhibitors. * Adequate organ function defined as; Absolute neutrophil count of more than 1.5×109 cells per L, more than 100×109 platelets per L, conjugated bilirubin serum concentration of up to 1.5 times the upper limit of normal, serum concentrations of alkaline phosphatase and aminotransferases of up to 2.5 times the upper limit of normal, and creatinine clearance of more than 60 mL/ min. Exclusion Criteria: * History of hypersensitivity to alpha lipoic acid. * Pregnancy or lactation. * patients receiving medications that interact with alpha lipoic acid, such as: * Iron supplements * Thyroid medications * Patients with severe cognitive impairments, neurological disorders (e.g., dementia, Alzheimer's disease), or severe psychiatric conditions that would interfere with the ability to comply with study protocols or follow-up * Uncontrolled heart disease (e.g., recent myocardial infarction, congestive heart failure) * Severe hypertension not controlled by medication * Patients with brain metastases.